ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
KOLs note that CagriSema could cannibalise semaglutide's market share in obesity due to its improved weight loss and HbA1c reduction efficacy.
Read the full article on the original site.
Read Full Article